CGYE21013 / NRG-GY020 / Richard Moore
Basic Study Information
Purpose:Location: Highland Hospital
This phase III trial compares whether the addition of pembrolizumab to radiation therapy
is more effective than radiation therapy alone in reducing the risk of cancer coming
back (recurrence) in patients with newly diagnosed stage I-II endometrial cancer.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells
and shrink tumors. The addition of pembrolizumab to radiation treatment may be more
effective than radiation treatment alone in reducing cancer recurrence.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search